NITE News and Press, Nightstar Therapeutics plc From 03/25/19

Just two weeks ago I looked at Biogen ( BIIB ) as it was "adding to the pipeline" with the acquisition of Nightstar Therapeutics ( NITE ) in an $800 million deal. That news was just noise in the devastating news which Biogen has seen in its pipeline, warranting an update on the investmen...

Biogen ( BIIB ) announced that it would acquire Nightstar Therapeutics ( NITE ) for $25.50 per share. All said and done this purchase was worth $800 million. This latest deal by Biogen highlights the hype about either partnering with or acquiring gene therapy biotechs. That's because t...

Double Helix Image NIH Sangamo ( SGMO ) closed the book on 2018 last week when they hosted their 4Q18 earnings call . 2018 had started with tremendous promise following the October 2017 first-ever in vivo genome editing treatment and a second Pfizer (NYSE: PFE ) gene regulation co...

Gainers: Nightstar Therapeutics (NASDAQ: NITE ) +66% . China Internet Nationwide Financial Services (NASDAQ: CIFS ) +64% . Ascendis Pharma A/S (NASDAQ: ASND ) +62% . China Finance Online (NASDAQ: JRJC ) +46% . Phunware (NASDAQ: PHUN ) +23% . Key Energy Services (NYSE: KEG ) +20% . B...

Nightstar Therapeutics Plc (NASDAQ: NITE )  +66%  on being acquired by Biogen. More news on: Nightstar Therapeutics plc, Ascendis Pharma, China Internet Nationwide Financial Services Inc., Stocks on the move, Read more ...

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...

WALTHAM, Mass. and LONDON, United Kingdom, Sept. 13, 2018 (GLOBE NEWSWIRE) --  Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company has appointed strategic biotechnolo...

Welcome to Seeking Alpha’s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Did we miss a notable deal? Let us know in the comments. Chinese produce: Goldman Sachs (GS) Investment Part...

Nightstar Therapeutics (NASDAQ: NITE ) is a clinical-stage biotechnology company focused on the development of gene therapies for the treatment of rare inherited retinal diseases. While the company is still at least 2 to 3 years away from commercializing its lead product candidate, I could s...

Cardiovascular Systems (NASDAQ: CSII ) initiated with Buy rating and $45 (18% upside) at Stifel citing valuation and expected return to double-digit growth next year. More news on: Cardiovascular Systems, Inc., Nightstar Therapeutics plc, Wright Medical Group, Inc., Healthcare stocks news,...